Patents by Inventor Lee E. Goldstein
Lee E. Goldstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150119273Abstract: The invention is based on the surprising discovery that as few as one episode of blast exposure increases the risk of CTE. Blast exposure is associated with chronic traumatic encephalopathy, impaired neuronal function, and persistent cognitive deficits in blast-exposed military veterans and experimental animals. Early diagnosis and assessment of risk permits physicians to prescribe treatment to reduce or slow progression of impairment before the onset of overt symptoms that become apparent decades after an initial insult or trauma to brain tissue. The invention provides methods and compositions for diagnosis and prognosis of individuals at risk of long term complications related to blast injury or concussive injury.Type: ApplicationFiled: May 16, 2013Publication date: April 30, 2015Inventors: Lee E. Goldstein, Ann C. Mckee, Neil W. Kowall
-
Patent number: 8388134Abstract: A system for performing quasi-elastic light scattering and fluorescent ligand scanning on a subject's eye includes a light source configured to transmit light toward the subject's eye, a lens configured to focus light sent from the source and scattered by the subject's eye, a measurement reflector disposed to receive at least a portion of the focused light and configured to reflect a first portion of the received light, a camera configured and disposed to receive the first portion of the received light and configured to provide indicia of an image corresponding to the first portion of the received light, and a processor coupled to the camera and configured to analyze intensities of light in the image to determine a location of a reference point corresponding to an interface of a portion of the eye.Type: GrantFiled: October 4, 2010Date of Patent: March 5, 2013Assignee: Cognoptix, Inc.Inventors: Lee E. Goldstein, Norman C. Ford, Leo T. Chylack, Jr., Paul D. Hartung, Marc D. Friedman, Evan A. Sherr, Stephen D. Fantone
-
Patent number: 8168393Abstract: The invention provides methods for diagnosing tumors in mammals using a reagent that bind to LEDGF/p75 or to a nucleic acid encoding LEDGF/p75. For example, the tumor may be located in the CNS, the prostate, the skin, the bone marrow, or the gut of the mammal. Also provided are methods for diagnosing brain tumors such as medulloblastomas, meningiomas, astrocytomas, glioblastomas multiforme, and ependymomas by examining LEDGF/p75 or a nucleic acid encoding LEDGF/p75 localization. The invention also involves methods for diagnosing cancers involving cancerous epithelial cells such as colon cancer. The instant invention also provides methods for isolating stem cells from a heterogeneous population of cells, as well as methods for identifying neuroepithelial stem cells, newly differentiated neurons, and astrocytes in a subject.Type: GrantFiled: February 13, 2008Date of Patent: May 1, 2012Assignee: The Brigham and Women's Hospital, Inc.Inventors: Lee E. Goldstein, Ling Fu
-
Publication number: 20110080559Abstract: A system for performing quasi-elastic light scattering and fluorescent ligand scanning on a subject's eye includes a light source configured to transmit light toward the subject's eye, a lens configured to focus light sent from the source and scattered by the subject's eye, a measurement reflector disposed to receive at least a portion of the focused light and configured to reflect a first portion of the received light, a camera configured and disposed to receive the first portion of the received light and configured to provide indicia of an image corresponding to the first portion of the received light, and a processor coupled to the camera and configured to analyze intensities of light in the image to determine a location of a reference point corresponding to an interface of a portion of the eye.Type: ApplicationFiled: October 4, 2010Publication date: April 7, 2011Inventors: Lee E. Goldstein, Norman C. Ford, Leo T. Chylack, JR., Paul D. Hartung, Marc D. Friedman, Evan A. Sherr, Stephen D. Fantone
-
Patent number: 7828436Abstract: A system for performing quasi-elastic light scattering and fluorescent ligand scanning on a subject's eye includes a light source configured to transmit light toward the subject's eye, a lens configured to focus light sent from the source and scattered by the subject's eye, a measurement reflector disposed to receive at least a portion of the focused light and configured to reflect a first portion of the received light, a camera configured and disposed to receive the first portion of the received light and configured to provide indicia of an image corresponding to the first portion of the received light, and a processor coupled to the camera and configured to analyze intensities of light in the image to determine a location of a reference point corresponding to an interface of a portion of the eye.Type: GrantFiled: April 11, 2007Date of Patent: November 9, 2010Assignee: Neuroptix CorporationInventors: Lee E. Goldstein, Norman C. Ford, Leo T. Chylack, Jr., Paul D. Hartung, Marc D. Friedman, Evan A. Sherr, Stephen D. Fantone
-
Patent number: 7653428Abstract: The invention provides a method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.Type: GrantFiled: August 28, 2006Date of Patent: January 26, 2010Assignee: The Brigham and Women's Hospital, Inc.Inventors: Lee E. Goldstein, Leo T. Chylack, Jr., Ashley Ian Bush
-
Publication number: 20090053712Abstract: The invention provides methods for diagnosing tumors in mammals using a reagent that bind to LEDGF/p75 or to a nucleic acid encoding LEDGF/p75. For example, the tumor may be located in the CNS, the prostate, the skin, the bone marrow, or the gut of the mammal. Also provided are methods for diagnosing brain tumors such as medulloblastomas, meningiomas, astrocytomas, glioblastomas multiforme, and ependymomas by examining LEDGF/p75 or a nucleic acid encoding LEDGF/p75 localization. The invention also involves methods for diagnosing cancers involving cancerous epithelial cells such as colon cancer. The instant invention also provides methods for isolating stem cells from a heterogeneous population of cells, as well as methods for identifying neuroepithelial stem cells, newly differentiated neurons, and astrocytes in a subject.Type: ApplicationFiled: February 13, 2008Publication date: February 26, 2009Inventors: Lee E. Goldstein, Ling Fu
-
Publication number: 20090041666Abstract: The invention provides ophthalmic formulations of Amyloid-? contrast agents. Also provided are methods of using such formulations in the diagnosis of Alzheimer's Disease or a predisposition thereto as well as methods for the prognosis of Alzheimer's Disease.Type: ApplicationFiled: May 21, 2008Publication date: February 12, 2009Inventors: Lee E. Goldstein, Evan A. Sherr, Paul D. Hartung, Francis X. Smith, Kevin R. Sullivan
-
Patent number: 7297326Abstract: The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer's Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.Type: GrantFiled: November 18, 2003Date of Patent: November 20, 2007Assignees: The General Hospital Corporation, The Brigham and Women's Hospital, Inc.Inventors: Lee E. Goldstein, Leo T. Chylack, Jr.
-
Patent number: 7166472Abstract: Described are methods for the identification of agents useful in the treatment or prevention of cataracts. Also described are methods for the identification of agents that may inadvertently promote or accelerate the formation of cataracts, and methods of treating or preventing injuries to or diseases of the ocular lens, retina and/or macula. More specifically, the invention describes methods for the identification of pharmacological agents useful in treating cataracts by inhibiting the cross-linking of eye lens proteins.Type: GrantFiled: November 9, 2004Date of Patent: January 23, 2007Assignee: The General Hospital CorporationInventors: Lee E. Goldstein, Ashley I. Bush
-
Patent number: 7107092Abstract: A method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.Type: GrantFiled: August 21, 2001Date of Patent: September 12, 2006Assignees: The General Hospital Corporation, The Brigham and Women's Hospital, Inc.Inventors: Lee E. Goldstein, Leo T. Chylack, Jr., Ashley Ian Bush
-
Patent number: 6849249Abstract: The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer's Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.Type: GrantFiled: April 25, 2002Date of Patent: February 1, 2005Assignees: The Brigham and Women's Hospital, Inc., The General Hospital CorporationInventors: Lee E. Goldstein, Leo T. Chylack, Jr.
-
Publication number: 20040152068Abstract: The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer's Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.Type: ApplicationFiled: November 18, 2003Publication date: August 5, 2004Inventors: Lee E. Goldstein, Leo T. Chylack
-
Publication number: 20020182152Abstract: The invention features a method of diagnosing or providing a prognosis regarding the state of Alzheimer's Disease in a mammal by contacting an ocular tissue with a detectably-labeled compound, which binds to an amyloid protein. An increase in binding of the compound to the ocular tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.Type: ApplicationFiled: April 25, 2002Publication date: December 5, 2002Inventors: Lee E. Goldstein, Leo T. Chylack
-
Publication number: 20020091321Abstract: The invention provides a method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.Type: ApplicationFiled: August 21, 2001Publication date: July 11, 2002Inventors: Lee E. Goldstein, Leo T. Chylack, Ashley Ian Bush